

This is a self-archived version of an original article. This version may differ from the original in pagination and typographic details.

Author(s): E, Repapi; I, Sayers; LV, Wain; RB, Burton; T, Johnson; M, Obeidat; JH, Zhao; A, Ramasamy; G, Zhai; V, Vitart; JE, Huffman; W, Igl; E, Albrecht; P, Deloukas; J, Henderson; J, Granell; WL, McArdle; AR, Rudnicka; Consortium, Wellcome Trust Case Control; I, Barroso; RJF, Loos; NJ, Wareham; L, Mustelin; Rantanen, Taina; I, Surakka; M, Imboden; HE, Wichmann; I, Grkovic; S, Jankovic; L, Zgaga; A,

Title: Genome-wide association study identifies five loci associated with lung function

Year: 2010

Version: Accepted version (Final draft)

Copyright: © 2009, Springer Nature

Rights: In Copyright

Rights url: <http://rightsstatements.org/page/InC/1.0/?language=en>

Please cite the original version:

E, R., I, S., LV, W., RB, B., T, J., M, O., JH, Z., A, R., G, Z., V, V., JE, H., W, I., E, A., P, D., J, H., J, G., WL, M., AR, R., Consortium, W. T. C. C., . . . MD, T. (2010). Genome-wide association study identifies five loci associated with lung function. *Nature Genetics*, 42(1), 36-44.
<https://doi.org/10.1038/ng.501>

Published in final edited form as:

Nat Genet. 2010 January ; 42(1): 36–44. doi:10.1038/ng.501.

Genome-wide association study identifies five loci associated with lung function

Emmanouela Repapi^{1,64,*}, Ian Sayers^{2,64}, Louise V Wain^{1,64}, Paul R Burton¹, Toby Johnson³, Ma'en Obeidat², Jing Hua Zhao⁴, Adaikalavan Ramasamy^{5,6}, Guangju Zhai⁷, Veronique Vitart⁸, Jennifer E Huffman⁸, Wilmar Igl⁹, Eva Albrecht¹⁰, Panos Deloukas¹¹, John Henderson¹², Raquel Graneli¹³, Wendy L McArdle¹⁴, Alicja R Rudnicka¹⁵, Wellcome Trust Case Control Consortium¹⁶, Inês Barroso¹¹, Ruth J F Loos⁴, Nicholas J Wareham⁴, Linda Mustelin¹⁷, Taina Rantanen¹⁸, Ida Surakka^{19,20}, Medea Imboden²¹, H Erich Wichmann^{10,22,23}, Ivica Grkovic²⁴, Stipan Jankovic²⁴, Lina Zgaga²⁵, Anna-Liisa Hartikainen²⁶, Leena Peltonen^{11,19,20}, Ulf Gyllensten⁹, Åsa Johansson⁹, Ghazal Zabolli⁹, Harry Campbell²⁷, Sarah H Wild²⁷, James F Wilson²⁷, Sven Gläser²⁸, Georg Homuth²⁹, Henry Völzke³⁰, Massimo Mangino⁷, Nicole Soranzo^{7,11}, Tim D Spector⁷, Ozren Polašek^{25,31}, Igor Rudan^{24,27,31}, Alan F Wright⁸, Markku Heliövaara²⁰, Samuli Ripatti^{19,20}, Anneli Pouta³², Åsa Torinsson Naluai³³, Anna-Carin Olin³⁴, Kjell Torén³⁴, Matthew N

© 2010 Nature America, Inc. All rights reserved.

Correspondence should be addressed to M.D.T. (mt47@leicester.ac.uk) or I.P.H. (ian.hall@nottingham.ac.uk).

*A full list of author affiliations appears at the end of the paper.

⁶⁴These authors contributed equally to this work.

AUTHOR CONTRIBUTIONS Author contributions are listed in alphabetical order. See Table 1 for definitions of study acronyms.

Project conception, design and management. *Stage 1 GWAS, ALSPAC:* J. Henderson, R.G. *B58C:* D.P.S. *EPIC:* I.B., R.J.F.L., N.J.W., J.H.Z. *FTC:* J.K., T.R. *KORA S3:* H.E.W. *Korcula:* H.C., I.G., S.J., I.R., A.F.W., L.Z. *NFBC1966:* P.E., M.-R.J., A.P., L.P. *NSPHS:* U.G. *ORCADES:* H.C., S.H.W., J.F.W., A.F.W. *SHIP:* S.G., G.H., B.K., H.V. *TwinsUK:* T.D.S., G. Zhai. *Vis:* H.C., C.H., O.P., I.R., A.F.W. *Stage 2a follow-up, ADONIX:* A.-C.O., K.T. *BHS:* A.L.J., L.J.P. *GS:SFHS:* H.C., C.J., A.D.M., D.J.P. *HCS:* C.C., E.D., J.W.H. *KORA F4:* S.K., E.S., H.S. *NFBC1986:* A.-L.H., M.-R.J. *Nottingham Smokers:* I.P.H., I. Sayers, M.O. *NSHD:* The NSHD Respiratory Study Team. *Stage 2b in silico follow-up, Health 2000:* M.H., M.K., L.P.

Phenotype collection and data management. *Stage 1 GWAS, ALSPAC:* J. Henderson, R.G. *B58C:* D.P.S., A.R.R. *EPIC:* N.J.W. *FTC:* J.K., L.M., T.R. *KORA S3:* H.E.W. *Korcula:* I.G., S.J., O.P., I.R., L.Z. *NFBC1966:* P.E., M.-R.J., A.-L.H., A.P. *NSPHS:* G. Zabolli. *ORCADES:* H.C., S.H.W., J.F.W. *SHIP:* S.G., B.K., H.V. *TwinsUK:* M.M., T.D.S. *Vis:* H.C., C.H., O.P., I.R., A.F.W. *Stage 2a follow-up, ADONIX:* A.-C.O., K.T. *BHS:* M.N.C., A.L.J., L.J.P. *BRHS:* R.W.M., S.G.W., P.H.W. *BWHHS:* G.D.S., S.E., D.A.L., P.H.W. *Gedling:* J.R.B., T.M.M., I.D.P. *GS:SFHS:* C.J., D.J.P. *HCS:* C.C., E.D., S.S. *KORA F4:* S.K., E.S., H.S. *NFBC1986:* A.-L.H., M.-R.J. *Nottingham Smokers:* J.D.B., I.P.H., I. Sayers, M.O. *NSHD:* The NSHD Respiratory Study Team. *Stage 2b in silico follow-up, Health 2000:* M.H., M.K.

Genotyping. *Stage 1 GWAS, ALSPAC:* P.D. *B58C:* W.L.M., WTCCC. *EPIC:* I.B., R.J.F.L., N.J.W., J.H.Z. *FTC:* J.K., I. Surakka. *KORA S3:* M.I., N.M.P.-H., H.G. *NFBC1966:* P.E., M.-R.J., L.P. *ORCADES:* H.C., J.F.W. *SHIP:* G.H. *TwinsUK:* N.S. *Vis:* C.H., I.R., A.F.W. *Stage 2a follow-up, ADONIX:* A.T.N., F.N. *BRHS:* A.D.H., R.W.M., P.H.W. *GS:SFHS:* A.D.M. *HCS:* C.C., E.D., J.W.H. *KORA F4:* H.G. *NFBC1986:* N.B.-N., J.D., P.F., M.-R.J., L.P. *Nottingham Smokers:* I.P.H. *NSHD:* D.K., A.W. *STAGE 2b in silico follow-up, Health 2000:* L.P., S.R., I. Surakka.

Data analysis. *Stage 1 GWAS, ALSPAC:* D.M.E. *B58C:* A.R.R. *EPIC:* R.J.F.L., J.H.Z. *FTC:* I. Surakka., L.M. *KORA S3:* E.A., M.I., N.M.P.-H. *Korcula:* C.H., J.E.H., V.V. *NFBC1966:* A.R. *NSPHS:* W.I., A.J. *ORCADES:* C.H., V.V. *SHIP:* S.G., G.H., B.K., H.V. *TwinsUK:* G. Zhai. *Vis:* C.H., V.V. *Stage 2a follow-up, ADONIX:* A.T.N., F.N., A.-C.O., K.T. *BHS:* M.N.C., J. Hui., L.J.P. *BRHS:* R.W.M. *BWHHS:* D.A.L. *Gedling:* M.O., M.D.T. *GS:SFHS:* A.K.M. *HCS:* J.W.H., S.S. *KORA F4:* E.A., H.G. *NFBC1986:* A.R. *Nottingham Smokers:* M.O., I. Sayers, M.D.T. *NSHD:* The NSHD Respiratory Study Team. *Stage 2b in silico follow-up, Health 2000:* M.K., S.R., I. Surakka.

Meta-analysis group. P.R.B., I.P.H., T.J., E.R., D.P.S., M.D.T., L.V.W.

Bioinformatics and expression profiling groups. I.P.H., M.O., I. Sayers, E.R., M.D.T., L.V.W.

Writing group. P.E., I.P.H., E.R., I. Sayers, D.P.S., M.D.T., L.V.W.

METHODS Methods and any associated references are available in the online version of the paper at <http://www.nature.com/naturegenetics/>.

Note: Supplementary information is available on the Nature Genetics website.

COMPETING INTERESTS STATEMENT The authors declare competing financial interests: details accompany the full-text HTML version of the paper at <http://www.nature.com/naturegenetics/>.

Reprints and permissions information is available online at <http://npg.nature.com/reprintsandpermissions/>.

URLs. UCSC browser, <http://genome.ucsc.edu/>.

Cooper³⁵, Alan L James^{36,37}, Lyle J Palmer^{35,37}, Aroon D Hingorani³⁸, S Goya Wannamethee³⁹, Peter H Whincup¹⁵, George Davey Smith⁴⁰, Shah Ebrahim⁴¹, Tricia M McKeever^{42,43}, Ian D Pavord⁴⁴, Andrew K MacLeod⁴⁵, Andrew D Morris⁴⁶, David J Porteous⁴⁵, Cyrus Cooper^{47,48}, Elaine Dennison⁴⁷, Seif Shaheen⁵, Stefan Karrasch⁴⁹, Eva Schnabel¹⁰, Holger Schulz⁴⁹, Harald Grallert¹⁰, Nabila Bouatia-Naji⁵⁰, Jérôme Delplanque⁵⁰, Philippe Froguel^{50,51}, John D Blakely², The NSHD Respiratory Study Team^{6,52,53}, John R Britton^{42,43}, Richard W Morris³⁹, John W Holloway^{54,55}, Debbie A Lawlor⁴⁰, Jennie Hui^{37,56}, Fredrik Nyberg^{34,57}, Marjo-Riitta Jarvelin^{6,32,58,59}, Cathy Jackson⁶⁰, Mika Kähönen⁶¹, Jaakko Kaprio^{17,19,20}, Nicole M Probst-Hensch^{21,62}, Beate Koch²⁸, Caroline Hayward⁸, David M Evans⁴⁰, Paul Elliott^{6,63,64}, David P Strachan^{15,64}, Ian P Hall^{2,64}, and Martin D Tobin^{1,64}

¹Departments of Health Sciences and Genetics, Adrian Building, University of Leicester, Leicester, UK. ²Division of Therapeutics and Molecular Medicine, Nottingham Respiratory Biomedical Research Unit, University Hospital of Nottingham, Nottingham, UK. ³Clinical Pharmacology, William Harvey Research Institute, Barts and The London School of Medicine and Dentistry, Queen Mary, University of London, London, UK. ⁴Medical Research Council (MRC) Epidemiology Unit, Institute of Metabolic Science, Cambridge, UK. ⁵Respiratory Epidemiology and Public Health Group, National Heart and Lung Institute, Imperial College London, London, UK. ⁶Department of Epidemiology and Public Health, Imperial College London, St. Mary's Campus, London, UK. ⁷Department of Twin Research and Genetic Epidemiology, King's College London, London, UK. ⁸MRC Human Genetics Unit, Institute of Genetics and Molecular Medicine, Western General Hospital, Edinburgh, Scotland, UK. ⁹Department of Genetics and Pathology, Rudbeck Laboratory, Uppsala University, Uppsala, Sweden. ¹⁰Institute of Epidemiology, Helmholtz Zentrum München, German Research Center for Environmental Health, Neuherberg, Germany. ¹¹Wellcome Trust Sanger Institute, Cambridge, UK. ¹²Department of Community-Based Medicine, University of Bristol, Bristol, UK. ¹³Department of Social Medicine, University of Bristol, Bristol, UK. ¹⁴Avon Longitudinal Study of Parents and Children (ALSPAC) Laboratory, Department of Social Medicine, University of Bristol, Bristol, UK. ¹⁵Division of Community Health Sciences, St. George's University of London, London, UK. ¹⁶A full list of members is provided in the supplementary Note. ¹⁷Department of Public Health, University of Helsinki, Helsinki, Finland. ¹⁸Department of Health Sciences and Finnish Center for Interdisciplinary Gerontology, University of Jyväskylä, Jyväskylä, Finland. ¹⁹Institute for Molecular Medicine Finland FIMM, University of Helsinki, Helsinki, Finland. ²⁰National Institute for Health and Welfare, Helsinki, Finland. ²¹Department of Chronic Disease Epidemiology/NICER, Institute of Social and Preventive Medicine, University of Zürich, Zürich, Switzerland. ²²Institute of Medical Informatics, Biometry and Epidemiology, Ludwig-Maximilians-Universität, Munich, Germany. ²³Klinikum Grosshadern, Munich, Germany. ²⁴Croatian Centre for Global Health, The University of Split Medical School, Split, Croatia. ²⁵Andrija Stampar School of Public Health, Faculty of Medicine, University of Zagreb, Zagreb, Croatia. ²⁶Department of Clinical Sciences, Obstetrics and Gynecology, Institute of Clinical Medicine, University of Oulu, Oulu, Finland. ²⁷Centre for Population Health Sciences, University of Edinburgh, Edinburgh, Scotland, UK. ²⁸Department of Internal Medicine B—Cardiology, Intensive Care, Pulmonary Medicine and Infectious Diseases, University of Greifswald, Greifswald, Germany. ²⁹Interfaculty Institute for Genetics and Functional Genomics, University of Greifswald, Greifswald, Germany. ³⁰Institute for Community Medicine, SHIP/Clinical-Epidemiological Research, University of Greifswald, Greifswald, Germany. ³¹Gen-Info, Zagreb, Croatia. ³²Department of Lifecourse and Services, National Institute for Health and Welfare, Oulu, Finland. ³³Department of Microbiology and Immunology, Institute of Biomedicine. ³⁴Occupational and Environmental Medicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden. ³⁵Centre for Genetic Epidemiology and Biostatistics, University of Western Australia, Perth, Western Australia, Australia. ³⁶Department of Pulmonary Physiology/West Australian Sleep Disorders Research Institute, Sir Charles Gairdner Hospital, Western Australia, Australia.

³⁷Busselton Population Medical Research Foundation, Sir Charles Gairdner Hospital, Western Australia, Australia. ³⁸Department of Epidemiology and Public Health, University College London, London, UK. ³⁹Department of Primary Care and Population Health, University College London, London, UK. ⁴⁰MRC Centre for Causal Analyses in Translational Epidemiology, Department of Social Medicine, University of Bristol, Bristol, UK. ⁴¹Non-Communicable Diseases Epidemiology Unit, Department of Epidemiology and Population Health, London School of Hygiene and Tropical Medicine, London, UK. ⁴²Division of Epidemiology and Public Health, School of Community Health Sciences, University of Nottingham, Nottingham, UK. ⁴³Nottingham Respiratory Biomedical Research Unit, University of Nottingham, Nottingham, UK. ⁴⁴Institute for Lung Health, Glenfield Hospital, University Hospitals of Leicester National Health Service Trust, Leicester, UK. ⁴⁵Medical Genetics Section, Centre for Molecular Medicine, Institute of Genetics and Molecular Medicine, University of Edinburgh, Western General Hospital, Edinburgh, UK. ⁴⁶Biomedical Research Institute, Ninewells Hospital, University of Dundee, Dundee, UK. ⁴⁷MRC Epidemiology Resource Centre, University of Southampton, Southampton General Hospital, Southampton, UK. ⁴⁸National Institute for Health Research (NIHR) Musculoskeletal Biomedical Research Unit, University of Oxford, Oxford, UK. ⁴⁹Institute of Lung Biology and Disease, Helmholtz Zentrum München, German Research Center for Environmental Health, Neuherberg, Germany. ⁵⁰CNRS 8090–Institute of Biology, Pasteur Institute, Lille, France. ⁵¹Section of Genomic Medicine, Imperial College London, Hammersmith Hospital, London, UK. ⁵²A full list of members is provided in the supplementary Note. ⁵³MRC National Survey of Health and Development, MRC Unit for Lifelong Health and Ageing, London, UK. ⁵⁴Human Genetics Division University of Southampton, Southampton General Hospital, Southampton, UK. ⁵⁵Infection, Inflammation and Immunity Division, School of Medicine, University of Southampton, Southampton General Hospital, Southampton, UK. ⁵⁶Molecular Genetics, PathWest Laboratory Medicine WA, Nedlands, Western Australia, Australia. ⁵⁷AstraZeneca Research and Development, Mölndal, Sweden. ⁵⁸Institute of Health Sciences, University of Oulu, Oulu, Finland. ⁵⁹Biocenter Oulu, University of Oulu, Oulu, Finland. ⁶⁰Bute Medical School, University of St. Andrews, St. Andrews, Fife, UK. ⁶¹Department of Clinical Physiology, University of Tampere and Tampere University Hospital, Tampere, Finland. ⁶²Institute of Social and Preventive Medicine at Swiss Tropical Institute, University of Basel, Basel, Switzerland. ⁶³MRC–Health Protection Agency (HPA) Centre for Environment and Health, Imperial College London, London, UK.

Abstract

Pulmonary function measures are heritable traits that predict morbidity and mortality and define chronic obstructive pulmonary disease (COPD). We tested genome-wide association with forced expiratory volume in 1 s (FEV₁) and the ratio of FEV₁ to forced vital capacity (FVC) in the SpiroMeta consortium ($n = 20,288$ individuals of European ancestry). We conducted a meta-analysis of top signals with data from direct genotyping ($n = 32,184$ additional individuals) and *in silico* summary association data from the CHARGE Consortium ($n = 21,209$) and the Health 2000 survey ($n = 883$). We confirmed the reported locus at 4q31 and identified associations with FEV₁ or FEV₁/FVC and common variants at five additional loci: 2q35 in *TNSI* ($P = 1.11 \times 10^{-12}$), 4q24 in *GSTCD* (2.18×10^{-23}), 5q33 in *HTR4* ($P = 4.29 \times 10^{-9}$), 6p21 in *AGER* ($P = 3.07 \times 10^{-15}$) and 15q23 in *THSD4* ($P = 7.24 \times 10^{-15}$). mRNA analyses showed expression of *TNSI*, *GSTCD*, *AGER*, *HTR4* and *THSD4* in human lung tissue. These associations offer mechanistic insight into pulmonary function regulation and indicate potential targets for interventions to alleviate respiratory disease.

Measures of pulmonary function, such as FEV₁ and FEV₁/FVC ratio, are important predictors of population morbidity and mortality¹⁻⁴ as well as forming the basis for the diagnosis of COPD. It is well established that pulmonary function is partially genetically

determined. Twin studies in European and US populations give heritability estimates for FEV₁ as high as 0.77 (refs. 5,6). Longitudinal studies in families suggest that genetic effects are consistent over time⁷. Genetic determinants of pulmonary function seem to operate, at least in part, independent of disease status (such as asthma) and smoking status⁸, suggesting that population-based association studies are a viable way to identify key genetic determinants of lung function.

Adequately powered genome-wide association studies (GWAS) using hundreds of thousands of common SNPs can identify loci associated with common diseases and the quantitative traits that underlie them. Collaborative studies achieving sample sizes in excess of 10,000 have been able to identify associations with common genetic variants with typically modest effect sizes (usually <0.1 s.d.)⁹. In the past year, GWAS have reported association between an intergenic locus at chromosome 4q31 and FEV₁/FVC ratio and COPD, but no large-scale collaborative GWAS have yet been undertaken for lung function^{10,11}.

If common SNPs underlying lung function have modest effects, very large sample sizes will be required to identify them. We therefore established the SpiroMeta consortium to facilitate large-scale meta-analysis of GWAS of lung function. Here we report a meta-analysis of GWAS in the SpiroMeta consortium, comprising 20,288 individuals of European ancestry, that tested association between cross-sectional lung function measures and ~2.5 million genotyped or imputed SNPs (stage 1). We followed up SNPs drawn from the most significantly associated loci in up to 32,184 individuals by direct genotyping (stage 2a) and using *in silico* summary association data relating to a further 22,092 individuals (stage 2b). These studies confirm the previous reported association at 4q31 and show that five previously unreported loci are robustly associated with lung function.

RESULTS

Genome-wide association with lung function (stage 1)

We included 14 studies of individuals of European ancestry, with sample sizes totaling 20,288 (Table 1). All individuals had measures of FEV₁ and FVC and smoking status recorded. FEV₁ and (separately) FEV₁/FVC measures were adjusted for age, age², sex, height and ancestry principal components within each study. Genome-wide genotyping was undertaken with a variety of platforms, and standard quality control measures were used (Online Methods and Supplementary Table 1). Genotypes were imputed for ~2.5 million autosomal SNPs from HapMap CEU data and tested for association separately for the inverse-normal transformed residuals of FEV₁ and FEV₁/FVC under an additive genetic model. We carried out meta-analysis of study-specific test statistics using an inverse variance weighting. We applied genomic control at the study and meta-analysis levels to avoid overinflation of test statistics owing to population structure or relatedness. Test statistic inflation before applying genomic control at the meta-analysis level was modest ($\lambda_{GC} = 1.046$ for FEV₁ and 1.035 for FEV₁/FVC). The plots of meta-analysis test statistics against expected values under the null hypothesis showed an excess of extreme values even after exclusion of the previously reported¹¹ 4q31 locus near *HHIP*, indicative of additional loci associated with lung function (Supplementary Fig. 1a,b).

We observed independent regions of association at 17 loci with $P < 1 \times 10^{-5}$ for FEV₁ and 23 for FEV₁/FVC (Figs. 1a,b and 2), including three regions (4q24 in *GSTCD*, 4q31 near *HHIP* and 15q23 in *THSD4*) that reached $P < 5 \times 10^{-8}$ in the stage 1 GWAS data alone, corresponding to a threshold of $P < 0.05$ after adjusting for 1 million independent tests¹². SNP rs12504628, which was associated with both FEV₁/FVC ($P = 6.48 \times 10^{-13}$; Fig. 2c and Table 2) and FEV₁ ($P = 1.50 \times 10^{-10}$; Table 3), lies in an intergenic region upstream of

HHIP and spanning ~300 kb at 4q31 that has been associated with lung function¹¹, COPD¹¹ and height⁹. Our top SNP rs12504628 was in strong linkage disequilibrium (LD; $r^2 = 0.97$) with the previously reported SNP associated with lung function, rs13147758 ($P = 5.30 \times 10^{-10}$ for FEV₁ and $P = 1.11 \times 10^{-12}$ for FEV₁/FVC in our data), and with SNPs associated previously with height (rs6854783, $r^2 = 0.55$; rs2055059, $r^2 = 0.48$), suggesting a role in skeletal growth and development. The hedgehog gene family, of which *HHIP* is a member, encodes signaling molecules involved in regulating lung morphogenesis, suggesting other mechanisms underlying these associations¹³. This intergenic region also contains multiple ESTs in human fetal lung (UCSC Browser).

Follow-up analyses (stage 2)

To validate potential associations with lung function, we selected 10 SNPs for further genotyping in additional studies of European ancestry (stage 2a, 32,184 individuals; Supplementary Table 2) and 30 SNPs for *in silico* follow-up (stage 2b; Supplementary Table 3). We obtained the *in silico* association results from the Health 2000 study (883 individuals) and from the CHARGE Consortium (21,209 individuals). Meta-analysis of the association results across stages 1, 2a and 2b showed five novel loci reaching genome-wide significance ($P < 5 \times 10^{-8}$): 2q35 in *TNSI*, 4q24 in *GSTCD*, 5q33 in *HTR4*, 6p21 in *AGER* and 15q23 in *THSD4* (Table 2 and Fig. 2). A further locus, 6p21 in *DAAM2*, which was not selected for further genotyping follow-up in stage 2a, fell just below the threshold for genome-wide significance for association with FEV₁/FVC after meta-analysis across stages 1 and 2b (rs2395730, $P = 7.98 \times 10^{-8}$; Supplementary Table 3 and Table 2).

The strongest association of FEV₁ was at 4q24 in *GSTCD* (rs10516526, $P = 2.18 \times 10^{-23}$; Table 2 and Fig. 2b). Relatively little is known about *GSTCD*, but the presence of the C-terminal α -helical domain common to the glutathione *S*-transferase (GST) family of enzymes suggests this protein is involved in cellular detoxification by catalyzing conjugation of glutathione to products of oxidative stress¹⁴. GST enzymes also show glutathione peroxidase activity regulating the synthesis of prostaglandins and leukotrienes¹⁴. To explore the potential function of *GSTCD*, we conducted a protein homology search and identified homology with chloride intracellular channels 1, 3, 4, 5 and 6, suggesting a role for *GSTCD* beyond the GST enzyme family. Genes in the region also include *INTS12* and *NPNT*. *INTS12* associates with RNA polymerase II and mediates 3'-end processing of small nuclear RNA¹⁵.

The second locus associated with FEV₁ was at 2q35, localized to the *TNSI* gene (nonsynonymous coding SNP rs2571445, $P = 1.11 \times 10^{-12}$; Table 2 and Fig. 2a). The protein this encodes, tensin-1, is an actin-binding protein that contains Src homology 2 domains, suggesting a role in linking cytoskeletal changes with signal transduction¹⁶. Tensin-1 may be functionally involved in cell migration¹⁷.

Multiple genes potentially underlie the third locus associated with FEV₁ at 5q33. The most strongly associated SNPs in this region, rs3995090 and rs6889822 ($P = 4.29 \times 10^{-9}$ and $P = 8.17 \times 10^{-9}$; Table 2 and Fig. 2d), are located in an intron in *HTR4* and are part of a cluster of associated SNPs also spanning a *SPINK5*-like gene, *SPINK7*, *SPINK9* and *FBXO38*. *HTR4*, which encodes 5-hydroxytryptamine receptor-4, is expressed in neurons in the respiratory pre-Bötzinger complex. Activation of this G protein-coupled receptor protects spontaneous respiratory activity¹⁸. Notably, selective antagonism of *HTR4* in human bronchial strips *in vitro* attenuates the facilitation of electric field-stimulated cholinergic contraction by 5-hydroxytryptamine, suggesting a role for *HTR4* in mediating airway caliber¹⁹. *HTR4* expression has recently been confirmed in airway epithelial type II cells, where receptor stimulation seems to regulate cytokine responses²⁰. The *SPINK* family of serine protease inhibitors may have a role in antimicrobial protection of mucous epithelia²¹.

F-box protein-38 (encoded by *FBXO38*) is a member of a family of proteins that are believed to mediate protein-protein interactions and protein degradation²².

The strongest association with FEV₁/FVC was at 6p21, a gene-rich region of the major histocompatibility complex (MHC). The extended LD in this region of the MHC prevented accurate localization of the association signal. However, we observed the peak of association for a nonsynonymous coding SNP in *AGER* (rs2070600, $P = 3.07 \times 10^{-15}$; Table 2 and Fig. 2e), which is a plausible candidate for causal association. *AGER*, also known as RAGE, is a multiligand receptor of the immunoglobulin superfamily²³. *AGER* is highly expressed in the lung, in particular alveolar epithelial cells²⁴, with a potential role in epithelium–extracellular matrix interactions. Reduced *AGER* expression has been identified in individuals with idiopathic pulmonary fibrosis²⁵, and *Ager*^{-/-} mice develop age-related pulmonary fibrosis²⁶. Another candidate in this region is the nearby gene *NOTCH4*, a member of the family of transmembrane receptors involved in cell fate decisions²⁷. Notch4 is expressed in endothelial cells of the adult mouse lung, where it is believed to regulate angiogenesis²⁸.

The second identified association with FEV₁/FVC was at 15q23, encompassing the *THSD4* gene (rs12899618, $P = 7.24 \times 10^{-15}$; Table 2 and Fig. 2f). *THSD4* shows homology with members of the thrombospondin family of extracellular calcium-binding proteins that modulate cellular attachment, proliferation and migration and have been implicated in wound healing, inflammation and angiogenesis²⁹.

For each of the loci we reported, the estimated effect sizes were broadly consistent across the GWAS (Fig. 3).

Association of variants with FVC

We tested the top SNP at each of the loci showing genome-wide significant association ($P < 5 \times 10^{-8}$) with FEV₁ or FEV₁/FVC for association with the other of the two traits, and with FVC in the stage 1 studies (Table 3). In addition to being associated with FEV₁, rs10516526 in *GSTCD* was associated with FVC ($P = 2.53 \times 10^{-7}$) but showed no discernible effect on FEV₁/FVC.

Effect of smoking on SNP associations

Adjustment for ever-smoking status in the stage 1 data (Table 3) did not show materially different effect-size estimates for the associations with the sentinel SNPs in *TNSI*, *GSTCD*, *HTR4*, *AGER*, *THSD4* or *HHIP*. Similarly, adjustments for a quantitative measure of lifetime smoking exposure (pack-years) did not show substantially different effect-size estimates for the identified SNP associations (data not shown). We also tested the associations of the top SNPs in *TNSI*, *GSTCD*, *HTR4*, *AGER* and *THSD4* separately in ever-smokers and never-smokers (Supplementary Table 4); all P values were >0.05 for tests of interaction between smoking status and these SNPs on lung function.

Gene expression

We determined the mRNA expression profiles of *GSTCD*, *HHIP*, *THSD4*, *TNSI*, *HTR4*, *AGER* and *NOTCH4* in human lung tissue and a series of primary cells. We detected all transcripts in lung tissue (Supplementary Fig. 2a) and bronchial epithelial cells (Supplementary Fig. 2b); six transcripts (excluding *NOTCH4*) were present in human airway smooth muscle cells. We also detected *GSTCD*, *TNSI*, *HTR4*, *AGER* and *NOTCH4* transcripts in peripheral blood mononuclear cells (Supplementary Fig. 2b). For *AGER*, we noted the presence of two PCR products suggesting an unreported splice variant; we confirmed the presence of the splice variant by sequencing.

DISCUSSION

Our study reports a meta-analysis of GWAS results from 20,288 participants and follow-up analyses in 54,276 participants, identifying five novel genome-wide significant loci for pulmonary function. The regions identified were 4q24 (*GSTCD*), 2q35 (*TNSI*) and 5q33 (*HTR4*) for FEV₁, and 6p21 (*AGER*) and 15q23 (*THSD4*) for FEV₁/FVC. In addition, we identified a region suggestive of association with FEV₁/FVC at 6p21 in *DAAM2*. The companion manuscript from the CHARGE Consortium, which reports a GWAS of lung function in 20,890 participants, also identifies genome-wide significant associations at *GSTCD*, *HTR4* and *AGER30*. Both SpiroMeta and CHARGE confirmed the previously reported association between FEV₁ and FEV₁/FVC and the 4q31 locus upstream of *HHIP1*.

Our findings have several important implications. First, the loci identified were observed in the whole population studied and were not specific to smokers. The presence of genetic determinants of lung function that do not depend on prior smoking exposure has been suggested by previous studies of heritability⁸. This does not rule out a possible subset of genetic determinants with effects on lung function that are partially or wholly dependent on smoking exposure.

We have also attempted to address the issue of genetic factors that influence smoking behavior. We did not observe any association with the *CHRNA3-CHRNA5-CHRNA4* locus previously reported to be associated with cigarette smoke exposure, lung cancer, peripheral arterial disease³¹ and COPD¹⁰ (rs1051730, $P = 0.23$ for FEV₁ and 0.56 for FEV₁/FVC). The associations we show in *GSTCD*, *TNSI*, *HTR4*, *THSD4* and *AGER* do not seem to be attenuated by adjustment for qualitative or quantitative adjustments for smoking exposure. None of these loci have been implicated in published GWAS of smoking quantity, although a recent report suggested a role for *THSD4* variants in smoking cessation³².

SNPs showing association with height could also show association with lung function measures because of incomplete adjustment for height, or because of SNP effects on skeletal growth with consequences for both height and lung function. The 4q31 locus near *HHIP* has shown convincing association with height³³. An association was recently reported between height and rs185819 at 6p21 (ref. 34). Although this association signal was broad, reflecting the extended LD across this region of the MHC, rs185819 was in weak LD ($r^2 = 0.069$) with rs2070600 (the sentinel SNP we reported for FEV₁/FVC in *AGER*). These findings leave open the possibility of shared genetic determinants of growth of pulmonary function and height, but they do not suggest that our findings are primarily accounted for by inadequate adjustment for height.

The level of FEV₁ at a given time point in an individual depends on two potentially independent processes: the maximum lung function obtained during development, and the rate of decline of lung function with age. Lung function reaches a maximum by age 25–35 years³⁵. The populations studied in SpiroMeta cover a wide range of ages except the very elderly; as expected, FEV₁ and FVC values were much lower in children. At least for the loci we identify, there was little evidence for age-specific effects, suggesting that the genetic risk factors identified operate across the age ranges; these findings again are in keeping with those of previous epidemiological studies⁷. Our analyses were based on cross-sectional measures of lung function; additional studies in cohorts with longitudinal data will be needed to identify determinants of the gradients of development and decline in lung function with age.

The magnitude of the estimated effect on untransformed FEV₁ of rs10516526 in *GSTCD* was 52 ml per copy of the G allele (frequency, 0.06). This is equivalent to about 3 years of

FEV₁ decline in the nonsmoking population³⁵. Allelic effect sizes on FEV₁ of the more common variants (minor allele frequencies ~0.4) were 19–23 ml for rs3995090 in *HTR4* and rs2571445 in *TNSI*. Individually, the five loci we describe account for a small proportion (0.07%–0.14%) of the variance in FEV₁ and in FEV₁/FVC (Table 2) in the general population.

After exclusion of the locus near *HHIP* and the five reported regions, meta-analysis test statistics still showed an excess of extreme values compared with expected values under the null, particularly for FEV₁. Although we cannot rule out the possibility of residual population stratification, this indicates the potential to detect further loci associated with lung function (Supplementary Fig. 1a,b). We have provided a list of the top 2000 associations for FEV₁ and for FEV₁/FVC (Supplementary Table 5) as a resource to other investigators.

We imputed nongenotyped SNPs using two software implementations^{36,37} that share similar underlying population genetic models³⁸. This methodology facilitates meta-analysis across different marker sets and improves coverage across the genome, and its utility has been empirically shown in several large GWAS. However, the power to detect associations with rare alleles is limited. The loci we report include two relatively infrequent SNPs, *GSTCD* (rs10516526, minor allele frequency 0.06) and *AGER* (rs2070600, minor allele frequency 0.05); these SNPs were directly genotyped in the majority of stage 1 subjects (16,514 and 15,386 individuals, respectively).

The associations we report relate to the general population but were of comparable magnitude after the exclusion of documented cases of asthma or COPD (data not shown). Although pulmonary function is an important predictor of morbidity and mortality *per se*, it will be important to investigate, in appropriately powered studies, whether the risk alleles in the genes identified in this study act as independent susceptibility markers for COPD or influence the development of airway obstruction in other diseases, such as asthma.

Our expression profiling studies identified expression of all of the candidate genes in relevant tissues. Further work is required to elucidate the mechanisms underlying the novel association signals we describe. In broad terms, however, it is notable that the most probable candidate genes in the regions identified seem to be involved either in developmental pathways important for lung growth or in tissue remodeling pathways that might be expected to alter airway architecture.

In conclusion, the results presented here from the SpiroMeta consortium, together with those reported by the CHARGE Consortium³⁰, provide strong evidence for newly identified genetic loci that act as important determinants of pulmonary function.

ONLINE METHODS

Study design

The study consisted of two stages. In stage 1, a meta-analysis was conducted on directly genotyped and imputed SNPs from 14 studies of individuals of European ancestry, with a total sample size of 20,288. Details of these studies are given in Table 1. This meta-analysis provided loci for further genotyping in up to 32,184 individuals of European origin (stage 2a) and *in silico* comparisons in 22,092 individuals of European origin (stage 2b).

Stage 1 samples

The SpiroMeta consortium consists of 14 GWAS studies: ALSPAC, B58C-T1DGC, B58C-WTCCC, EPIC (obese and population-based substudies), the EUROSPAN studies (Korcula,

NSPHS, ORCADES and Vis), FTC (incorporating the FinnTwin16 and Finnish Twin Study on Aging), KORA S3, NFBC1966, SHIP and TwinsUK (see Table 1 for definitions of acronyms). The primary analyses on FEV₁ and FEV₁/FVC included 20,288 individuals of European descent. The measurements of FEV₁ and FVC are described in the Supplementary Note.

Genome-wide genotyping and quality control

The platforms used were Affymetrix 500K GeneChip array (four studies), Illumina HumanHap 550 Beadchip (one study), Illumina 317K (four studies), Affymetrix Genome-Wide SNP6.0 (one study), Illumina Hap370cnv (one study), Illumina Hap300 v1 (one study) and Illumina Hap300 v2 (two studies). Each individual study applied quality-control criteria as described in Supplementary Table 1.

Imputation

Imputation of nongenotyped SNPs was undertaken with MACH36 or IMPUTE37 with preimputation filters and parameters as shown in Supplementary Table 1. SNPs were excluded if the imputation information, assessed using r2.hat (MACH) or .info (IMPUTE), was <0.3. In total, 2,705,257 autosomal SNPs were analyzed.

Transformation of data and genotype-phenotype association analysis

Linear regression of age, age², sex, height and ancestry principal components was undertaken on FEV₁ (milliliters) and FEV₁/FVC (percentage). The residuals were transformed to ranks and subsequently to normally distributed *z* scores, and were then used as the phenotype for association testing under an additive genetic model using software specified in Supplementary Table 1. Appropriate tests for association in related individuals were applied where necessary, as described in the Supplementary Note.

Meta-analysis of stage 1 data

All stage 1 study effect estimates were corrected using genomic control⁴⁰ and were oriented to the forward strand of the NCBI build 36 reference sequence of the human genome, consistently using the alphabetically higher allele as the coded allele. Study-specific lambda estimates are shown in Supplementary Table 1. The pooled effect-size estimate and s.e.m. were computed using inverse variance weighting, and genomic control was applied to the pooled effect-size estimates. To describe the effect of imperfect imputation on power, we report '*N* effective', the sum of the study-specific products of the sample size and the imputation quality metric. Meta-analysis statistics and figures were produced using R version 2.7.0.

Selection of SNPs for stage 2

Ten leading SNPs were selected for stage 2a genotyping follow-up (Supplementary Table 2). Thirty leading SNPs were selected for stage 2b *in silico* exchange, according to *P* value (under the threshold of 5×10^{-5}), *N* effective (70% of the total sample size) and evidence from supporting SNPs (Supplementary Table 3).

Stage 2a samples (follow-up genotyped data)

We genotyped 10 SNPs in up to 32,184 individuals from the ADONIX, BHS, BRHS, BWHHS, Gedling, GS:SFHS, HCS, KORA F4, NFBC1986, Nottingham Smokers and NSHD studies. The characteristics of the studies are summarized in Table 1, and stage 2a study information is provided in the Supplementary Note.

Stage 2b samples (*in silico* data)

The CHARGE Consortium includes four population-based studies with data on FEV₁ and FEV₁/FVC: the Atherosclerosis Risk in Communities (ARIC) study, the Cardiovascular Health Study (CHS), the Framingham Heart Study (FHS) and the Rotterdam Study (RS). Details are provided in the companion paper in this issue from the CHARGE Consortium³⁰. Given differences between the analysis approaches for GWAS adopted by the SpiroMeta and CHARGE consortia, the CHARGE analyses were undertaken using the analysis approach adopted by the SpiroMeta consortium (21,209 individuals; larger than the sample in the companion paper, which excluded subjects with missing or incomplete pack-years data). We also included 883 population-based subjects from the Health 2000 study in the stage 2b analysis.

Combined analysis of stage 1 and 2 samples

Meta-analysis of data from stages 1, 2a and 2b was conducted using inverse variance weighting. We described associations as genome-wide significant if $P < 5 \times 10^{-8}$.

Secondary analyses

To examine the effect of smoking on the causal pathway between the SNPs and the traits of interest, an adjustment for smoking was applied. The subgroups of ‘ever-smokers’ and ‘never-smokers’ were analyzed separately, and the stratum-specific estimated effects were combined within each individual study using inverse variance weights before meta-analyzing over studies. Additional adjustments were undertaken by adjusting for pack-years among the ever-smokers with these data available, and repeating the analyses.

PCR expression profiling

The mRNA expression profiles of *GSTCD*, *HHIP*, *THSD4*, *TNSI*, *HTR4*, *AGER* and *NOTCH4* were determined in human lung tissue and primary cell samples using RT-PCR, including RNA from lung (Ambion/ABI), brain, airway smooth muscle cells⁴¹ and human bronchial epithelial cells (Clonetics⁴²). Peripheral blood mononuclear cells were isolated from whole blood using 6% (w/v) dextran and 42%–51% (v/v) Percoll gradients (Sigma). Ethical approval for the use of primary cells was obtained from the local ethics committees. Total RNA was extracted from samples using an RNeasy kit (Qiagen) as directed by the manufacturer. cDNA was generated from 1 µg of RNA template using random hexamers and a SuperScript kit (Invitrogen) as directed by the manufacturer. PCR assays were designed to cross intron-exon boundaries and where splice variation was known, in order to detect all variants. Primer sequences are given in Supplementary Table 6. All PCR was done using Platinum Taq High Fidelity (Invitrogen) with 100 ng of cDNA template in a 25-µl reaction. Cycling conditions were as follows: 94 °C for 3 min, 35 cycles of 94 °C for 45 s, 55 °C for 30 s, and 72 °C for 90 s.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgments

We thank the many colleagues who contributed to collection and phenotypic characterization of the clinical sampling, genotyping and analysis of the GWAS data. We especially thank those who kindly agreed to participate in the studies.

Major funding for this work is from the following sources (in alphabetical order): Academy of Finland (including project grants 104781, 120315 and 1114194) and Center of Excellence in Complex Disease Genetics; Arthritis Research Campaign; Asthma UK; AstraZeneca; Biocenter Oulu, University of Oulu; Biocentrum Helsinki;

Biotechnology and Biological Sciences Research Council project grant; British Heart Foundation (including project grants PG/06/154/22043 and PG/97012 and Senior Research Fellowship FS05/125); British Lung Foundation; Cancer Research United Kingdom; Chief Scientists Office, part of the Scottish Government Health Directorate (including grant CZD/16/6); Department of Health Air Pollution PRP (ref. no. 0020029); ENGAGE project (HEALTH-F4-2007-201413); European Commission (EURO-BLCS, FP-5/QLG1-CT-2000-01643, FP-7/2007-2013, FP-6 LSHB-CT-2006-018996 (GABRIEL), FP-6 LSHG-CT-2006-01947 (EUROSPAN), HEALTH-F2-2008-201865-GEFOS and FP-5 GenomEUtwin project QLG2-CT-2002-01254); Finnish Ministry of Education; German Federal Ministry of Education and Research (BMBF, including grants 01ZZ96030, 01ZZ0701 and 01GI0883 and German Asthma and COPD Network (COSYCONET) grant 01GI0883); German Ministry for Education, Research and Cultural Affairs; German National Genome Research Network (NGFN-2 and NGFN-plus); Healthway, Western Australia; HEFCE Science Research Investment Fund; Helmholtz Zentrum München; German Research Center for Environmental Health, Neuherberg, Germany; International Osteoporosis Foundation; Juvenile Diabetes Research Foundation International; Leicester Biomedical Research Unit in Cardiovascular Science (NIHR); Medical Research Council UK (including grants G0500539, G0501942, G0000943 and G990146); Medical Research Fund of the Tampere University Hospital; Ministry for Social Affairs of the Federal State of Mecklenburg-West Pomerania; MRC Human Genetics Unit; Munich Center of Health Sciences, as part of LMUinnovativ; National Human Genome Research Institute; National Institute for Health Research comprehensive Biomedical Research Centre award to Guy's & St. Thomas' NHS Foundation Trust in partnership with King's College London; National Institute for Health Research Cambridge Biomedical Research Centre; National Institute of Allergy and Infectious Diseases; National Institute of Child Health and Human Development; National Institute of Diabetes and Digestive and Kidney Diseases; National Heart, Lung, and Blood Institute (grant 5R01HL087679-02 through the STAMPEED program (1RL1MH083268-01)); Oulu University Hospital; PHOEBE (FP6, LSHG-CT-2006-518418); Public Population Project in Genomics (Genome Canada and Genome Quebec), Republic of Croatia Ministry of Science, Education and Sports (research grant 108-1080315-0302); Royal Society; Siemens Health Care Sector; Swedish Heart and Lung Foundation (grant 20050561); Swedish Medical Research Council (project no. K2007-66X-20270-01-3); Swedish Research Council for Working Life and Social Research (FAS, grants 2001-0263 and 2003-0139); the Great Wine Estates of the Margaret River region of Western Australia; UBS Wealth Foundation (grant BA29s8Q7-DZZ); UK Department of Health Policy Research Programme; University of Nottingham; University of Bristol; US National Institutes of Health (U01 DK062418); US National Institutes of Health–National Institute of Mental Health (5R01MH63706:02); Wellcome Trust (including grants 068545/Z/02, 076113/B/04/Z, 079895, 077016/Z/05/Z, 075883 and 086160/Z/08/A); and Zentren für Innovationskompetenz (BMBF grant 03ZIK012).

References

1. Myint PK, et al. Respiratory function and self-reported functional health: EPIC-Norfolk population study. *Eur. Respir. J.* 2005; 26:494–502. [PubMed: 16135734]
2. Schünemann HJ, Dorn J, Grant BJ, Winkelstein W Jr. Trevisan, Pulmonary function is a long-term predictor of mortality in the general population: 29-year follow-up of the Buffalo Health Study. *Chest.* 2000; 118:656–664. [PubMed: 10988186]
3. Strachan DP. Ventilatory function, height, and mortality among lifelong non-smokers. *J. Epidemiol. Community Health.* 1992; 46:66–70. [PubMed: 1573363]
4. Young RP, Hopkins R, Eaton TE. Forced expiratory volume in one second: not just a lung function test but a marker of premature death from all causes. *Eur. Respir. J.* 2007; 30:616–622. [PubMed: 17906084]
5. Hubert HB, Fabsitz RR, Feinleib M, Gwinn C. Genetic and environmental influences on pulmonary function in adult twins. *Am. Rev. Respir. Dis.* 1982; 125:409–415. [PubMed: 7200340]
6. McClearn GE, Svartengren M, Pedersen NL, Heller DA, Plomin R. Genetic and environmental influences on pulmonary function in aging Swedish twins. *J. Gerontol.* 1994; 49:264–268. [PubMed: 7963289]
7. Lewitter FI, Tager IB, McGue M, Tishler PV, Speizer FE. Genetic and environmental determinants of level of pulmonary function. *Am. J. Epidemiol.* 1984; 120:518–530. [PubMed: 6475921]
8. Palmer LJ, et al. Familial aggregation and heritability of adult lung function: results from the Busselton Health Study. *Eur. Respir. J.* 2001; 17:696–702. [PubMed: 11401066]
9. Loos RJ, et al. Common variants near MC4R are associated with fat mass, weight and risk of obesity. *Nat. Genet.* 2008; 40:768–775. [PubMed: 18454148]
10. Pillai SG, et al. A genome-wide association study in chronic obstructive pulmonary disease (COPD): identification of two major susceptibility loci. *PLoS Genet.* 2009; 5:e1000421. [PubMed: 19300482]

11. Wilk JB, et al. A genome-wide association study of pulmonary function measures in the Framingham Heart Study. *PLoS Genet.* 2009; 5:e1000429. [PubMed: 19300500]
12. McCarthy MI, et al. Genome-wide association studies for complex traits: consensus, uncertainty and challenges. *Nat. Rev. Genet.* 2008; 9:356–369. [PubMed: 18398418]
13. Miller L-AD, et al. Role of Sonic hedgehog in patterning of tracheal-bronchial cartilage and the peripheral lung. *Dev. Dyn.* 2004; 231:57–71. [PubMed: 15305287]
14. Hayes JD, Flanagan JU, Jowsey IR. Glutathione transferases. *Annu. Rev. Pharmacol. Toxicol.* 2005; 45:51–88. [PubMed: 15822171]
15. Baillat D, et al. Integrator, a multiprotein mediator of small nuclear RNA processing, associates with the C-terminal repeat of RNA polymerase II. *Cell.* 2005; 123:265–276. [PubMed: 16239144]
16. Weigt C, Gaertner A, Wegner A, Korte H, Meyer HE. Occurrence of an actin-inserting domain in tensin. *J. Mol. Biol.* 1992; 227:593–595. [PubMed: 1404377]
17. Chen H, Duncan IC, Bozorgchami H, Lo SH. Tensin1 and a previously undocumented family member, tensin2, positively regulate cell migration. *Proc. Natl. Acad. Sci. USA.* 2002; 99:733–738. [PubMed: 11792844]
18. Manzke T, et al. 5-HT₄(a) receptors avert opioid-induced breathing depression without loss of analgesia. *Science.* 2003; 301:226–229. [PubMed: 12855812]
19. Dupont LJ, et al. The effects of 5-HT on cholinergic contraction in human airways in vitro. *Eur. Respir. J.* 1999; 14:642–649. [PubMed: 10543288]
20. Bayer H, et al. Serotonergic receptors on human airway epithelial cells. *Am. J. Respir. Cell Mol. Biol.* 2007; 36:85–93. [PubMed: 16873768]
21. Mägert HJ, et al. LEKTI, a novel 15-domain type of human serine proteinase inhibitor. *J. Biol. Chem.* 1999; 274:21499–21502. [PubMed: 10419450]
22. Kipreos ET, Pagano M. The F-box protein family. *Genome Biol.* 2000; 1 REVIEWS3002.
23. Sparvero LJ, et al. RAGE (Receptor for Advanced Glycation Endproducts), RAGE ligands, and their role in cancer and inflammation. *J. Transl. Med.* 2009; 7:17. [PubMed: 19292913]
24. Fehrenbach H, et al. Receptor for advanced glycation endproducts (RAGE) exhibits highly differential cellular and subcellular localisation in rat and human lung. *Cell. Mol. Biol.* 1998; 44:1147–1157. [PubMed: 9846897]
25. Konishi K, et al. Gene expression profiles of acute exacerbations of Idiopathic Pulmonary Fibrosis. *Am. J. Respir. Crit. Care Med.* 2009; 180:167–175. [PubMed: 19363140]
26. Englert JM, et al. A role for the receptor for advanced glycation end products in idiopathic pulmonary fibrosis. *Am. J. Pathol.* 2008; 172:583–591. [PubMed: 18245812]
27. Fortini ME. Notch signaling: the core pathway and its posttranslational regulation. *Dev. Cell.* 2009; 16:633–647. [PubMed: 19460341]
28. Favre CJ, et al. Expression of genes involved in vascular development and angiogenesis in endothelial cells of adult lung. *Am. J. Physiol. Heart Circ. Physiol.* 2003; 285:H1917–H1938. [PubMed: 12842817]
29. Chen H, Herndon ME, Lawler J. The cell biology of thrombospondin-1. *Matrix Biol.* 2000; 19:597–614. [PubMed: 11102749]
30. Hancock DB, et al. Meta-analyses of genome-wide association studies identify multiple loci associated with pulmonary function. *Nat. Genet.* Dec 13.2009 advance online publication, doi: 10.1038/ng.500.
31. Thorgeirsson TE, et al. A variant associated with nicotine dependence, lung cancer and peripheral arterial disease. *Nature.* 2008; 452:638–642. [PubMed: 18385739]
32. Uhl GR, et al. Molecular genetics of successful smoking cessation: convergent genome-wide association study results. *Arch. Gen. Psychiatry.* 2008; 65:683–693. [PubMed: 18519826]
33. Weedon MN, et al. Genome-wide association analysis identifies 20 loci that influence adult height. *Nat. Genet.* 2008; 40:575–583. [PubMed: 18391952]
34. Gudbjartsson DF, et al. Many sequence variants affecting diversity of adult human height. *Nat. Genet.* 2008; 40:609–615. [PubMed: 18391951]

35. Kohansal R, et al. The natural history of chronic airflow obstruction revisited: an analysis of the framingham offspring cohort. *Am. J. Respir. Crit. Care Med.* 2009; 180:3–10. [PubMed: 19342411]
36. Li Y, Abecasis GR. Mach 1.0: Rapid haplotype reconstruction and missing genotype inference. *Am. J. Hum. Genet.* 2006; S79:2290.
37. Marchini J, Howie B, Myers S, McVean G, Donnelly P. A new multipoint method for genome-wide association studies by imputation of genotypes. *Nat. Genet.* 2007; 39:906–913. [PubMed: 17572673]
38. Guan Y, Stephens M. Practical issues in imputation-based association mapping. *PLoS Genet.* 2008; 4:e1000279. [PubMed: 19057666]
39. Myers S, Bottolo L, Freeman C, McVean G, Donnelly P. A fine-scale map of recombination rates and hotspots across the human genome. *Science.* 2005; 310:321–324. [PubMed: 16224025]
40. Devlin B, Roeder K. Genomic control for association studies. *Biometrics.* 1999; 55:997–1004. [PubMed: 11315092]
41. Sayers I, Swan C, Hall IP. The effect of beta2-adrenoceptor agonists on phospholipase C (beta1) signalling in human airway smooth muscle cells. *Eur. J. Pharmacol.* 2006; 531:9–12. [PubMed: 16412418]
42. Wadsworth SJ, Nijmeh HS, Hall IP. Glucocorticoids increase repair potential in a novel in vitro human airway epithelial wounding model. *J. Clin. Immunol.* 2006; 26:376–387. [PubMed: 16786432]




Figure 1. Manhattan plots of association results for FEV₁ and FEV₁/FVC (analysis stage 1). **(a,b)** Manhattan plots ordered by chromosome position. SNPs for which $-\log_{10} P > 5$ are indicated in red. The six loci indicated by arrows showed association with FEV₁ **(a)** or FEV₁/FVC **(b)**; $P < 5 \times 10^{-8}$) in the meta-analysis of data from stages 1, 2a and 2b.




Figure 2.

Regional association plots of six lung function–associated loci. (**a–f**) Statistical significance of each SNP on the $-\log_{10}$ scale as a function of chromosome position (NCBI build 36) in the meta-analysis of stage 1 data alone. The sentinel SNP at each locus is shown in blue; the correlations (r^2) of each of the surrounding SNPs to the sentinel SNP are shown in the indicated colors. The six loci included are those that showed association with FEV₁ or FEV₁/FVC ($P < 5 \times 10^{-8}$) in the meta-analysis of data from stages 1, 2a and 2b. The combined P values for all stages are indicated by arrows. The relevant trait (FEV₁ or FEV₁/FVC ratio) is indicated for each plot. For rs12504628, the plot shows only the association of FEV₁/FVC; this SNP was associated ($P < 5 \times 10^{-8}$) with both FEV₁ and FEV₁/FVC. Fine-scale recombination rate is plotted in blue³⁹. Combined P value from stages 1 and 2a only; SNP rs3995090 had low imputation quality in the CHARGE Consortium data and so was not included in stage 2b.




Figure 3. Forest plots of the stage 1 meta-analysis for the six lung function-associated loci. Each of the SNPs included in the figure showed genome-wide significant association ($P < 5 \times 10^{-8}$) with either FEV₁ or FEV₁/FVC in the data from stages 1, 2a and 2b. The plots show the meta-analysis of the stage 1 data for each sentinel SNP. The contributing effect (transformed beta) from each study is shown by a square, with confidence intervals indicated by horizontal lines. The contributing weight of each study to the meta-analysis is indicated by the size of the square. The combined meta-analysis estimate in the stage 1 data is shown at the bottom of each graph.

Table 1

study characteristics

Study	N total	N male	N female	Age range (y) at FEV ₁ /FVC measurement	Mean age, y (s.d.)	Mean FEV ₁ , l (s.d.)	Mean FVC, l (s.d.)	Mean FEV ₁ /FVC (s.d.)	N neversmokers	N ever-smokers
Stage 1: GWAS										
ALSPAC	1,391	676	715	8–9	8.7 (0)	1.70 (0.26)	1.93 (0.31)	0.88 (0.07)	1,391	0
B58C TIDGC	2,343	1,131	1,212	44–45	44.5 (0)	3.31 (0.78)	4.19 (0.96)	0.79 (0.08)	692	1,651
B58C WTCCC	1,372	691	681	44–45	44.5 (0)	2.93 (0.75)	4.18 (0.96)	0.79 (0.08)	394	978
EPIC obese cases	1,104	476	628	39–76	59.1 (8.8)	2.35 (0.69)	2.84 (0.87)	0.82 (0.17)	489	615
EPIC population based	2,336	1,100	1,236	39–77	59.2 (9.0)	2.50 (0.72)	3.04 (0.90)	0.85 (0.16)	1,061	1,275
FTC	134	13	121	23–76	57.4 (19.3)	2.69 (0.94)	2.93 (0.61)	0.79 (0.09)	104	30
KORA S3	555	261	294	29–73	47.6 (9.0)	3.43 (0.78)	4.18 (0.99)	0.83 (0.07)	266	289
Koreula	825	300	525	18–90	55.5 (13.5)	2.84 (0.81)	3.37 (0.93)	0.84 (0.09)	397	428
NFBC1966	4,556	2,182	2,374	31–31	31.0 (0)	3.96 (0.79)	4.73 (0.99)	0.84 (0.06)	1,648	2,908
NSPHS	549	255	294	18–91	50.0 (19.1)	3.02 (0.95)	3.68 (1.12)	0.82 (0.09)	464	85
ORCADES	692	322	370	19–93	54.9 (15.3)	2.88 (0.84)	3.58 (0.98)	0.80 (0.09)	404	288
SHIP	1,777	870	907	25–85	52.3 (13.7)	3.28 (0.89)	3.87 (1.03)	0.87 (0.06)	773	1,004
TwinsUK	1,885	0	1,885	18–79	48.4 (12.2)	2.73 (0.56)	3.40 (0.61)	0.80 (0.08)	943	942
Vis	769	323	446	18–88	56.3 (15.3)	3.39 (1.22)	4.38 (1.43)	0.77 (0.09)	328	441
Stage 1 sample size	20,288									
Stage 2a: studies with direct genotyping										
ADONIX	1,338	635	703	25–75	49.2 (13.6)	3.35 (0.86)	4.24 (1.02)	0.79 (0.07)	743	595
BHS	4,350	1,793	2,557	18–96	50.1 (17.0)	3.02 (0.97)	3.89 (1.16)	0.77 (0.08)	2,459	1,891
BRHS	3,897	3,897	0	60–79	68.7 (5.5)	2.57 (0.69)	3.37 (0.84)	0.77 (0.11)	1,132	2,765
BWHHS	3,644	0	3,644	59–80	68.8 (5.5)	1.98 (0.52)	2.82 (0.76)	0.71 (0.09)	2,060	1,584
Gedling	1,263	632	631	27–80	56.2 (12.3)	2.85 (0.85)	3.68 (1.02)	0.77 (0.07)	633	630
GS-SFHS	5,474	2,254	3,220	18–89	46.0 (14.3)	3.15 (0.87)	4.11 (1.03)	0.77 (0.10)	3,005	2,469
HCS	2,850	1,511	1,339	59–73	66.1 (2.8)	2.44 (0.68)	3.42 (0.92)	0.72 (0.09)	1,319	1,531
KORA F4	1,305	610	695	41–61	51.6 (5.7)	3.32 (0.81)	4.28 (1.00)	0.78 (0.06)	499	806
NFBC1986	4,946	2,379	2,567	15–17	16.0 (0.38)	3.77 (0.70)	4.30 (0.84)	0.88 (0.08)	3,708	1,238
Nottingham Smokers	509	280	229	40–89	59.5 (10.4)	2.00 (0.95)	3.01 (1.06)	0.64 (0.16)	0	509

Study	N total	N male	N female	Age range (y) at FEV ₁ /FVC measurement	Mean age, y (s.d.)	Mean FEV ₁ , l (s.d.)	Mean FVC, l (s.d.)	Mean FEV ₁ /FVC (s.d.)	N neversmokers	N ever-smokers
NSHD	2,608	1,308	1,300	53–53	53 (0)	2.80 (0.70)	3.50 (0.89)	0.81 (0.19)	1,080	1,528
Stage 2a sample size	32,184									
Stage 2b: studies with <i>in silico</i> data										
Health 2000	883	427	456	30–75	50.2 (11.0)	3.32 (0.91)	4.19 (1.08)	0.79 (0.07)	266	617
CHARGE ^a (ref. 30)	21,209									
Stage 2b sample size	22,092									
Total sample size	74,564									

Characteristics are shown for studies analyzed in stage 1 (GWAS meta-analysis), stage 2a (direct genotyping follow-up, 10 SNPs) and stage 2b (*in silico* follow-up, 30 SNPs). Stage 1 studies: ALSPAC, Avon Longitudinal Study of Parents and Children; B58C-TIDGC, British 1958 Birth Cohort–Type 1 Diabetes Genetics Consortium; B58C-WTCCC, British 1958 Birth Cohort–Wellcome Trust Case Control Consortium; EPIC obese cases, European Prospective Investigation into Cancer and Nutrition, Obese Cases; EPIC population based, European Prospective Investigation into Cancer and Nutrition Cohort; FTC, Finnish Twin Cohort incorporating FinnTwin16 and FITSA; KORAS3, Cooperative Health Research in the Region of Augsburg; the Korcula study; NFBC1966, Northern Finland Birth Cohort; 1966; NSPHS, Northern Sweden Population Health Study; ORCADES, Orkney Complex Disease Study; SHIP, Study of Health in Pomerania; the TwinsUK study; the Vis study. Stage 2a studies: ADONIX, Adult-Onset Asthma and Nitric Oxide; BHS, Busselton Health Study; BRHS, British Regional Heart Study; BWHHS, British Women's Heart and Health Study; the Gedling study; GS:SFHS, Generation Scotland; Scottish Family Health Study; HCS, Hertfordshire Cohort Study; KORAS4, Cooperative Health Research in the Region of Augsburg; NFBC1986, Northern Finland Birth Cohort of 1986; the Nottingham Smokers study; NSHD, Medical Research Council National Survey of Health and Development (also known as the British 1946 Birth Cohort). Stage 2b studies: Health 2000, Finnish Health 2000 survey; CHARGE, Cohorts for Heart and Aging Research in Genomic Epidemiology.

^aCharacteristics of the constituent studies of the CHARGE Consortium are presented in the companion paper from the CHARGE Consortium³⁰.

Table 2

Loci associated with lung function

Chr.	Measure	SNP ID (NCBI36 position), function	Coded allele	Stage	Coded allele freq.	N	Beta (s.e.m.)	P	Joint meta-analysis of all stages			
									Beta (s.e.m.)	P	r ²	N total
2	FEV ₁	rs2571445 (218,391,399), <i>TNSI</i> (ns)	G	1	0.59	18,710	0.057 (0.011)	2.41 × 10 ⁻⁷	0.035 (0.005)	1.11 × 10 ⁻¹²	0.07%	70,329
				2a	0.60	29,922	0.031 (0.008)	9.03 × 10 ⁻⁵				
				2b	0.61	21,697	0.027 (0.007)	1.94 × 10 ⁻⁴				
4	FEV ₁	rs10516526 (106,908,353), <i>GSTCD</i> (intron)	G	1	0.06	20,179	0.135 (0.022)	6.67 × 10 ⁻¹⁰	0.089 (0.009)	2.18 × 10 ⁻²³	0.14%	73,488
				2a	0.06	31,217	0.092 (0.013)	8.51 × 10 ⁻¹²				
				2b	0.07	22,092	0.066 (0.014)	3.37 × 10 ⁻⁶				
4	FEV ₁ /FVC	rs12504628 (145,655,774), <i>HHP</i> (upstream)	T	1	0.56	19,400	-0.077 (0.011)	6.48 × 10 ⁻¹³	-0.077 (0.011)	6.48 × 10 ⁻¹³	0.27%	19,400
				2a	—	0	—	—				
				2b	—	0	—	—				
5	FEV ₁	rs3995090 (147,826,008), <i>HTR4</i> (intron)	C	1	0.41	18,792	0.058 (0.011)	1.36 × 10 ⁻⁷	0.038 (0.006)	4.29 × 10 ⁻⁹	0.07%	49,305
				2a	0.41	29,630	0.029 (0.008)	3.04 × 10 ⁻⁴				
				2b	0.36	883	-0.037 (0.050)	4.62 × 10 ⁻¹				
5	FEV ₁	rs6889822 (147,826,900), <i>HTR4</i> (intron)	G	1	0.40	19,652	0.057 (0.011)	1.73 × 10 ⁻⁷	0.034 (0.006)	8.17 × 10 ⁻⁹	0.08%	41,094
				2a	0.38	0	—	5.76 × 10 ⁻⁴				
				2b	0.424	21,442	0.025 (0.0072)	—				
6	FEV ₁ /FVC	rs2070600 (32,259,421), <i>ACER</i> (ns)	T	1	0.05	19,183	0.115 (0.023)	5.86 × 10 ⁻⁷	0.088 (0.011)	3.07 × 10 ⁻¹⁵	0.09%	67,410
				2a	0.06	26,229	0.069 (0.014)	7.90 × 10 ⁻⁷				
				2b	0.04	21,998	0.130 (0.031)	2.24 × 10 ⁻⁵				
6	FEV ₁ /FVC	rs2395730 (39,892,343), <i>DAAM2</i> (intron)	C	1	0.419	19,887	0.048 (0.011)	5.86 × 10 ⁻⁶	0.044 (0.008)	7.98 × 10 ⁻⁸	0.07%	41,447
				2a	0.424	0	—	—				
				2b	0.424	21,560	0.038 (0.013)	3.22 × 10 ⁻³				
15	FEV ₁ /FVC	rs1289618 (69,432,174), <i>THSD4</i> (intron)	G	1	0.84	19,875	0.082 (0.014)	7.17 × 10 ⁻⁹	0.060 (0.008)	7.24 × 10 ⁻¹⁵	0.09%	67,049
				2a	0.85	26,124	0.043 (0.011)	7.51 × 10 ⁻⁵				
				2b	0.85	21,050	0.072 (0.018)	4.21 × 10 ⁻⁵				

Shown are the top SNPs or SNPs for each independent locus associated ($P < 5 \times 10^{-7}$) with FEV₁ or FEV₁/FVC in a joint analysis of up to 74,564 individuals of European ancestry from the SpiroMeta GWAS (stage 1), follow-up genotyping (stage 2a) and *in silico* data from the CHARGE Consortium (companion paper in this issue³⁰) and the Health 2000 study (stage 2b). The six genome-wide significant ($P < 5 \times 10^{-8}$) loci are indicated in bold. Results are also shown for rs2395730 (*DAAM2*), as this locus fell just below genome-wide significance after meta-analysis of stage 1 and 2b data (it was not selected for stage 2a genotyped follow-up). For the GWAS (stage 1 and 2b) data, the sample sizes (*N*) shown are the effective sample sizes. Effective sample size within each study is the product of sample size and imputation quality metric. Total sample size is the sum of the *N* effective values across all stage 1 and 2b studies, plus the sample size from the directly genotyped (stage 2a) studies; for each SNP, this is lower than 74,564 individuals owing to missing genotypes and imperfect imputation. Joint meta-analysis includes data from stages 1, 2a and 2b. Beta values reflect effect-size estimates on an inverse-normal transformed scale after adjustments for age, age², sex, height and ancestry principal components. SNP rs12504628 showed association with both FEV₁ and FEV₁/FVC ($P < 5 \times 10^{-8}$); statistics for the strongest association (FEV₁/FVC) are shown. As this association has been previously published¹¹, rs12504628 was not assessed in the follow-up studies, so statistics are not presented for stages 2a and 2b for rs12504628. SNP rs3995090 was genotyped in stage 2a follow-up studies and was available in Health 2000 study data, but owing to low imputation quality for rs3995090 in the CHARGE Consortium data, an alternative SNP in the region, rs6889822, was selected for *in silico* exchange with the CHARGE Consortium. The estimated proportion of variance explained by each SNP in the joint meta-analysis is shown (r²), ns, nonsynonymous coding SNP.

Table 3

Relation of SNPs at genome-wide significant loci to FEV₁, FVC and FEV₁/FVC, and impact of adjustment for smoking in stage 1 (spiroMeta GWAs) data

SNP ID (NCBI36 position), function	Chr.	Coded allele	Noncoded allele	N	Measure	Unadjusted stage 1 analyses		Smoking-adjusted stage 1 analyses			
						Beta	s.e.m.	P	Beta	s.e.m.	P
rs2571445 (218391399), <i>TNSI</i> (ns)	2	G	A	18,710	FEV ₁	0.057	0.011	2.41 × 10 ⁻⁷	0.055	0.012	2.12 × 10 ⁻⁶
					FVC	0.041	0.011	1.84 × 10 ⁻⁴	0.038	0.011	8.94 × 10 ⁻⁴
					FEV ₁ /FVC	0.026	0.011	0.018	0.031	0.012	0.0073
rs10516526 (106908353), <i>GSTCD</i> (intron)	4	G	A	20,179	FEV ₁	0.135	0.022	6.67 × 10 ⁻¹⁰	0.138	0.023	2.06 × 10 ⁻⁹
					FVC	0.112	0.022	2.53 × 10 ⁻⁷	0.119	0.023	1.29 × 10 ⁻⁷
					FEV ₁ /FVC	0.038	0.022	0.084	0.030	0.023	0.19
rs12504628 (145655774), <i>HHIP</i> (upstream)	4	T	C	19,400	FEV ₁	-0.068	0.011	1.50 × 10 ⁻¹⁰	-0.069	0.011	7.18 × 10 ⁻¹⁰
					FVC	-0.021	0.011	0.046	-0.020	0.011	0.066
					FEV ₁ /FVC	-0.077	0.011	6.48 × 10 ⁻¹³	-0.080	0.011	8.25 × 10 ⁻¹³
rs3995090 (147826008), <i>HTR4</i> (intron)	5	C	A	18,792	FEV ₁	0.058	0.011	1.36 × 10 ⁻⁷	0.059	0.011	1.47 × 10 ⁻⁷
					FVC	0.023	0.011	0.034	0.031	0.011	0.0048
					FEV ₁ /FVC	0.045	0.011	1.92 × 10 ⁻⁵	0.038	0.011	7.0 × 10 ⁻⁴
rs6889822 (147826900), <i>HTR4</i> (intron)	5	G	A	19,652	FEV ₁	0.057	0.011	1.73 × 10 ⁻⁷	0.062	0.011	5.23 × 10 ⁻⁸
					FVC	0.025	0.011	0.021	0.034	0.011	0.0025
					FEV ₁ /FVC	0.046	0.011	2.15 × 10 ⁻⁵	0.038	0.011	7.3 × 10 ⁻⁴
rs2070600 (32259421), <i>AGER</i> (ns)	6	T	C	19,183	FEV ₁	0.027	0.023	0.24	0.044	0.024	0.072
					FVC	-0.043	0.023	0.063	-0.035	0.024	0.14
					FEV ₁ /FVC	0.115	0.023	5.86 × 10 ⁻⁷	0.126	0.024	2.42 × 10 ⁻⁷
rs12899618 (69432174), <i>THSD4</i> (intron)	15	G	A	19,875	FEV ₁	0.028	0.014	0.047	0.033	0.015	0.025
					FVC	-0.024	0.014	0.085	-0.024	0.015	0.11
					FEV ₁ /FVC	0.082	0.014	7.17 × 10 ⁻⁹	0.092	0.015	6.56 × 10 ⁻¹⁰

Each SNP included in table showed genome-wide significant association ($P < 5 \times 10^{-8}$) with either FEV₁ or FEV₁/FVC in data from stages 1, 2a and 2b. Beta values shown reflect effect-size estimates on an inverse-normal transformed scale in the stage 1 data. Effective sample size was calculated within each study as the product of sample size and imputation quality metric and were summed across studies to calculate total effective sample size (N). Estimates from analyses unadjusted for smoking status and adjusted for ever-smoking versus never-smoking status are shown.